The list of potential drugs against the COVID-19 continues to shrink: after hydroxychloroquine, clinical trials by european Solidarity and Discovery have also abandoned the treatment and lopinavir/ritonavir, was deemed ineffective and suspected adverse effects.
After this decision, these two trials will now focus more than on a single drug, the remdesivir, just get a placing on the market conditional within the european Union.
The combination of the two antiviral drugs, lopinavir and ritonavir, which is used against the aids virus (and sold under the name Kaletra), had already been discontinued at the end of June by another important clinical trial, the British Recovery.
The same decision was made jointly on Saturday by the WHO (world health Organization) for the trial Solidarity organised by the responsible French test partner, Discovery.
WHO has at the same time definitively endorsed the discontinuation of the hydroxychloroquine, decided on 17 June.
“The preliminary results show that hydroxychloroquine, and lopinavir/ritonavir does not reduce that little or no mortality of patients hospitalized for the COVID-19 compared to standard care,” said the WHO in a press release.
In addition, the test Discovery has highlighted ” the significantly higher frequency of serious adverse effects on the renal function in patients on lopinavir/ritonavir, said in a press release from INSERM, French research institute who is organizing this test.
This is particularly the case “in patients hospitalized in the icu,” says INSERM.
According to the WHO and INSERM, all of these results will be published in a scientific journal.
Although dozens of treatments against the COVID-19 are valued around the world, none to date has shown outstanding efficiency, with the exception of a steroid, dexamethasone, for patients the most affected.
According to the results of the test Recovery, dexamethasone reduces the mortality in patients with the most severely affected, those who are under mechanical ventilation.
For its part, the remdesivir was obtained on July 3, an authorisation for the placing on the market conditional within the EU granted by the european Commission
An american study has shown that this antiviral originally developed against the Ebola hemorrhagic fever reduced slightly the duration of recovery to the sick of the COVID-19 hospitalized (from 15 to 11 days in average). On the other hand, it has no proven benefits in terms of mortality reduction.